Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España

Actualizado septiembre 2021

Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Para iniciar la búsqueda, teclee el texto en la barra a continuación.

EudraCT-NumberNCTCÓDIGO-ESTUDIOTÍTULO ESTUDIO FASEINDICACIÓNESTADOMEDICACIÓNCENTROPROMOTOR
N.A4970134
TTCC-2020-02Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY ProjectObservacionalThis project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation.RECLUTANDON.AH.U. Clínic (Barcelona)
H.U. Miguel Servet (Zaragoza)
H.U. La Paz (Madrid)
H.U. La Fe (Valencia)
H.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. Marqués de Valdecilla (Santander)
ICO Hospitalet
H. General de Valencia
Fundación Althaia (Manresa)
H.U. Parc Taulí (Sabadell)
ICO Girona
TTCC
2018-002612-27​3780517
BOS172738-01A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer(MTC)Phase IThis study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.RECLUTANDOBOS172738H.U. Virgen de la Victoria (Málaga)
ICO Badalona
H.U. Dexeus (Barcelona)
Start_Sanchinarro (Madrid)
Start_F.J.Díaz (Madrid)
Boston Pharmaceuticals
2018-004334-15
4234113SC103A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid TumorsPhase IHNSCC & Thyroid, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selectedadvanced/metastatic solid tumorsRECLUTANDOSO-C101 PembrolizumaH.U. Vall d´Hebron (Barcelona)SOTIO
2017-001792-243170960XL184-021A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPhase IbExpansion Cohort 18:
DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
RECLUTANDOAtezolizumab
Cabozantinib
No especificado por promotorExelixis
2016-004390-413037385BLU-667-1101 (ARROW)A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (ARROW)Phase I/IIThis is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer,RECLUTANDOPralsetinib (BLU-667)H.U. Vall d´Hebron (Barcelona)
H.U. Clínic (Barcelona)
ICO Hospitalet
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
Blueprint Medicines Corporation
2017-000800-59
3157128
LOXO-RET-17001A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)Phase I/IIThis is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.RECLUTANDOLOXO-292H.U. Vall d´Hebron (Barcelona)
Start_F.J.Díaz (Madrid)
Start_Sanchinarro (Madrid)
Loxo Oncology, Inc
2015-002067-4126280673475-158A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Phase IIThyroid Carcinoma
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
RECLUTANDOPembrolizumabH.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
Merck Sharp & Dohme Corp
2018-001066-42
3753919GETNE-T1812Estudio de fase II de durvalumab (MEDI4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY) Phase IICarcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de Hürthle y poco diferenciado (CDT).
Carcinoma medular de tiroides (CMT) avanzado.
Cáncer anaplásico de tiroides (CAT) avanzado.
RECLUTANDODurvalumab
Tremelimumab
CUN
H.U. Vall d´Hebron (Barcelona)
ICO Hospitalet
H.U. Morales Meseguer (Murcia)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. Virgen de la Victoria (Málaga)
H.U. Clínic (Barcelona)
M.D. Anderson (Madrid)
H.U. Sanchinarro (Madrid)
H.U. Clínico San Carlos (Madrid)
C.H. Castellón
IVO Valencia
H.U. Alvaro Cunqueiro (Vigo)
Spanish Group of Neuroendocrine Tumors (GETNE)
2016-003616-133093116TPX-0005-01A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Phase II( in Spain)A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)RECLUTANDORepotrectinib (TPX-0005)CUN
H.U. Dexeus (Barcelona)
H.U. Vall d´Hebron (Barcelona)
M.D. Anderson (Madrid)
Start_F.J.Díaz (Madrid)
Start_Sanchinarro (Madrid)
H.U. 12 de Octubre (Madrid)
IVO Valencia
Turning Point Therapeutics, Inc.
2019-002279-32
4400474GETNE-T1914Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN StudyPhase IICABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.RECLUTANDO
cabozantinib
atezolizumab 
No especificado por promotorGrupo Español de Tumores Neuroendocrinos
2019-001978-284211337J2G-MC-JZJBA Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)Phase IIIThe reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.RECLUTANDOSelpercatinib
Cabozantinib
Vandetanib
H.U. Virgen de la Victoria (Málaga)
H.U. Clínico San Carlos (Madrid)
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. Ramón y Cajal (Madrid)
H.U. Gregorio Marañón (Madrid)
ICO Girona
ICO Hospitalet
H.U. Vall d´Hebron (Barcelona)
C.U.N.
H.U. Miguel Servet (Zaragoza)
Loxo Oncology, Inc
N.A3765333
REGETNE-TiroidesDescriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and AnaplasticDescriptive ObservationalNARECLUTANDONAH.U. Vall d´Hebron (Barcelona)GETNE

Puede seleccionar el número de filas a representar entre: 4, 8 o 10